Document is current

Article History

Received: 17 April 2025

Accepted: 11 August 2025

First Online: 1 September 2025

Declarations

:

: This trial has been prospectively registered at the EUCT number: 2023–509659-15–00, 15/07/2024. The trial protocol has been reviewed by the European Medicines Agency (Reference number: 2023–509659-15–00, 15/07/2024). In compliance with the Declaration of Helsinki of 1964, as revised in 2013, the International Conference of Harmonization Guidelines for Good Clinical Practice, and the guidelines of local ethics committees, written informed permission will be obtained by investigators from all subjects when patients are enrolled in the study.

: Marta Ostrowska-Lesko: Clinical trials: CELLTRION INC. Stocks and shares: M2 Innovations, EBMed.Marcin Bobinski: Clinical trials: Astra Zeneca, MSD, Aeterna Zentalis, Clovis, Corcept Therapeutics; Lectures and Grants: GSK, Astra Zeneca, Abbvie; Stocks and shares: M2 Innovations, Ryvu Therapeutics, PolTreg, ScopeFluidics.Radoslaw Madry: Lecturer: Abbvie, Amgen; AstraZeneca; GSK; Roche; MSD; Medisson. Research for: Amgen, Antisoma, AstraZeneca, Bayer, GSK, Glycotope GmbH, Janssen, Menarini, Morphotek, MSD, OSI Pharmaceuticals, PharmaMar, Roche, Sanofi, Sotio, Tesaro. Consultancy for: AstraZeneca, GSK, MSD, Pharma@, Roche.This study was not funded or supported by the above partners, and the author did not receive any financial benefits related to this research.